Quoin Pharmaceuticals, Ltd. R&D Expense

Quick Answer

Quoin Pharmaceuticals, Ltd. reported R&D Expense of $9.80 million for fiscal year 2025.

Quoin Pharmaceuticals, Ltd. R&D Expense — Annual History

Fiscal Year R&D Expense YoY Change
2025 $9.80M +172.1%
2024 $3.60M +8.9%
2023 $3.31M +23.8%
2022 $2.67M +71.0%
2021 $1.56M +540.1%
2020 $244.2K +434.8%
2019 $45.6K -99.7%
2018 $13.51M +217.5%
2017 -$11.50M -239.3%
2016 $8.26M +40.1%
2015 $5.89M

Quarterly R&D Expense

Quarter Ending R&D Expense YoY QoQ
September 30, 2025 $2.28M +111.3% +11.2%
June 30, 2025 $2.05M +249.0% -13.6%
March 31, 2025 $2.37M +168.2% +119.9%
September 30, 2024 $1.08M +42.3% +83.8%
June 30, 2024 $587.5K -6.0% -33.6%
March 31, 2024 $885.3K -18.9% +16.7%
September 30, 2023 $758.8K +1.8% +21.4%
June 30, 2023 $625.1K -14.0% -42.7%
  • Quoin Pharmaceuticals, Ltd. showed an increase of +172.1% in R&D Expense compared to the prior fiscal year.
  • Over the 2015–2025 period, Quoin Pharmaceuticals, Ltd.’s r&d expense has grown by 66.3% (from $5.89 million to $9.80 million).
  • The most recent figure is from Quoin Pharmaceuticals, Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment